Enhancement of mucosal immunization with virus-like particles of simian immunodeficiency virus
about
Intranasal immunization with influenza VLPs incorporating membrane-anchored flagellin induces strong heterosubtypic protectionEffect of mucosal and systemic immunization with virus-like particles of severe acute respiratory syndrome coronavirus in miceInfluenza vaccines based on virus-like particlesIncorporation of membrane-bound, mammalian-derived immunomodulatory proteins into influenza whole virus vaccines boosts immunogenicity and protection against lethal challengePIKA provides an adjuvant effect to induce strong mucosal and systemic humoral immunity against SARS-CoV.CpG DNA: trigger of sepsis, mediator of protection, or both?Incorporation of glycosylphosphatidylinositol-anchored granulocyte- macrophage colony-stimulating factor or CD40 ligand enhances immunogenicity of chimeric simian immunodeficiency virus-like particles.Mucosal innate immune response associated with a timely humoral immune response and slower disease progression after oral transmission of simian immunodeficiency virus to rhesus macaques.Intranasal Immunization with Influenza Virus-Like Particles Containing Membrane-Anchored Cholera Toxin B or Ricin Toxin B Enhances Adaptive Immune Responses and Protection against an Antigenically Distinct Virus.Intranasal immunization with inactivated influenza virus enhances immune responses to coadministered simian-human immunodeficiency virus-like particle antigens.Human immunodeficiency virus-like particles activate multiple types of immune cells.Mucosal and systemic immune responses of mice to tetanus toxoid coadministered nasally with AFCo1.Eliminating Factor H-Binding Activity of Borrelia burgdorferi CspZ Combined with Virus-Like Particle Conjugation Enhances Its Efficacy as a Lyme Disease Vaccine.Intranasal immunization with a recombinant truncated FimH adhesin adjuvanted with CpG oligodeoxynucleotides protects mice against uropathogenic Escherichia coli challenge.
P2860
Q28744570-7DAAAB0D-C4C4-4945-9862-33569790B75DQ28751866-13E04398-59A6-417F-BB22-8E72A151238AQ30376236-10DC0F43-4E2F-4ED3-924F-E192DEDD52C7Q30376482-E804CFBB-AEBD-4E80-A38D-4E38906FD995Q30401566-E32EC216-4022-43FF-946F-C033F212E8AEQ35585084-4AC068FB-44D2-46A2-9C75-CBA845CA81D1Q35635302-6878248D-269A-4BAE-9758-06EBE37DDBBEQ35857157-64FD9E9C-8C1F-4FA7-9A54-96F59BEA1A92Q36846046-CECBB77A-AD51-4420-9717-B9E8D98B86F2Q37492531-1338316F-82F6-494D-B7FC-E9888A38CE7EQ42034526-ACC5BDF2-7F70-4BF3-86A9-7ADA09F605DDQ44682289-9F9A129B-5FF1-46FC-A0F0-5FE21304709EQ50334209-B1099E88-429C-4D27-AF26-99AD03CCCB05Q54448728-EEEBFF2C-DD7B-4EDB-8017-63AA7F8ADC56
P2860
Enhancement of mucosal immunization with virus-like particles of simian immunodeficiency virus
description
2003 nî lūn-bûn
@nan
2003 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2003 թվականի մարտին հրատարակված գիտական հոդված
@hy
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
name
Enhancement of mucosal immuniz ...... simian immunodeficiency virus
@ast
Enhancement of mucosal immuniz ...... simian immunodeficiency virus
@en
Enhancement of mucosal immuniz ...... simian immunodeficiency virus
@nl
type
label
Enhancement of mucosal immuniz ...... simian immunodeficiency virus
@ast
Enhancement of mucosal immuniz ...... simian immunodeficiency virus
@en
Enhancement of mucosal immuniz ...... simian immunodeficiency virus
@nl
prefLabel
Enhancement of mucosal immuniz ...... simian immunodeficiency virus
@ast
Enhancement of mucosal immuniz ...... simian immunodeficiency virus
@en
Enhancement of mucosal immuniz ...... simian immunodeficiency virus
@nl
P2860
P1433
P1476
Enhancement of mucosal immuniz ...... simian immunodeficiency virus
@en
P2093
Richard W Compans
Sang-Moo Kang
P2860
P304
P356
10.1128/JVI.77.6.3615-3623.2003
P407
P577
2003-03-01T00:00:00Z